about
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsIncorporation of tissue-based genomic biomarkers into localized prostate cancer clinicsPSA and beyond: alternative prostate cancer biomarkersThe structure and function of NKAIN2-a candidate tumor suppressorProstate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal BiomarkersClinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical ProstatectomyImproving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling StudyEvaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasisMesothelial Inclusions in Pelvic Lymph Nodes Initially Diagnosed as Metastatic Prostate Cancer; the Utility of Second Opinions and Genomic Testing in the Setting of Unexpected Results.Molecular biomarkers to guide precision medicine in localized prostate cancer.Changes in prostate cancer grading: Including a new patient-centric grading system.Exome-based genome-wide association study and risk assessment using genetic risk score to prostate cancer in the Korean population.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Clinical variability and molecular heterogeneity in prostate cancer.Role of protein phosphatases in genitourinary cancers.Rationale for the development of alternative forms of androgen deprivation therapy.Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.Providing guidance for genomics-based cancer treatment decisions: insights from stakeholder engagement for post-prostatectomy radiation therapy.Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.Molecular heterogeneity of localized prostate cancer: more different than alike.Mitochondrial genome variation and prostate cancer: a review of the mutational landscape and application to clinical management.Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer.High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancerPTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles.Ethnicity and ERG frequency in prostate cancer.Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection.TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance.Precision Medicine and Men's Health.Best of the 2017 AUA Annual Meeting: Highlights From the 2017 American Urological Association Annual Meeting, May 12-16, 2017, Boston, MA.Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.Prostate cancer: Caveat Emptor - long-term outcomes in the Göteborg active surveillance cohort.How can we optimize the use of prostate cancer registries?3-T multiparametric MRI characteristics of prostate cancer patients suspicious for biochemical recurrence after primary focal cryosurgery (hemiablation).Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer.Management of prostate cancer: NYU Case of the Month, July 2017.
P2860
Q26750672-8EB35422-D53F-43FA-87AF-3C5ED54D0C02Q26752510-796A0B90-D654-4144-9F7D-CC64E2E252D2Q26770646-9AFD9876-933C-430B-9F2E-173FF0578507Q26771844-82485960-1F60-4220-AC8B-B08196C01F56Q28075610-87F073E6-C8BB-4774-8F5B-D044478AB379Q35885756-1A737E0A-C5D2-4B82-8A77-FEB058468EC9Q36092572-36A40786-4D58-45E5-B2B8-554511AE77F6Q37070927-820F8E2A-79B4-48D2-B798-6C3794C757B1Q37490793-62945AAE-1638-446A-9DD0-133CBABBF50AQ38668635-E9884C20-7A3C-4DED-AD59-98CA1725029CQ38680873-B1768FAF-1BFF-4C3D-8BCD-B41F08C63332Q38734618-AF2E1A98-C839-4637-9268-FA5407AB4E2BQ38774228-C2EC9838-2A36-408A-AF64-C015FA67255EQ38808811-67E26437-CE83-43A2-ABF6-9DA2408C560DQ38941676-430D2F66-99E2-4416-A491-BAAC99060266Q39342369-19C22D3B-1CA0-4E58-AA3A-23229CEB4950Q39566728-FD3F3D56-E448-4C54-8313-72C113346CC7Q40356316-B18F70C7-5BEA-43B7-B5D4-87B491B235B0Q40674443-B1A9F5C1-490C-4579-AD29-3021C178C08FQ40738452-AA78ECBD-C97C-4378-B9C8-5D88E5743DD5Q40919195-781D1351-9CC6-4593-B209-2EEDDC95D030Q41520709-19200F5E-5027-4CEA-9406-AFB7E639173BQ41660235-296B85C8-EACC-4F2D-B7F8-E66465F7938DQ42255184-764F785D-2A7E-4C2D-A5E8-525257DC5BA4Q42378534-ED54216B-A387-4C57-9566-C6FC3524F8F8Q42530532-02341DD5-C370-4423-876A-00F74F5188FDQ42539779-792F2D5A-8147-451A-A6C5-573EAF9AFC11Q46000712-65BB09D3-A9E2-485A-A05D-B8C72C83FD17Q46504038-8BF38B26-144B-4E5D-BF10-EE44E4E29E41Q46548482-21119BA8-5E95-4C71-97C6-488BB35C4CECQ46838481-981E068C-B360-47CC-8B4C-F243FC80BB60Q47149516-34202FB1-7479-4EA9-9671-4BFF6022B8D6Q47151829-BF2BBABC-877F-4D4E-B5B2-30EE0F571117Q47557967-3EAA460E-7D60-4A63-A00D-C7AA90503694Q47718669-A3BC6426-5634-43ED-920D-4847DF08EEAFQ48055935-04845E52-5D43-46E6-A6D9-3A2F3E7E4E21Q48196067-5F21BC9C-23A4-46B6-83A2-8AC8097AF147Q48254978-815F1A6A-F794-4887-8E8E-FA223A04F1A2Q48309899-9D440423-5E6A-4C1A-B3D4-B8B5CD2F38DEQ50184941-3B355EFC-36F2-4768-B0F1-AFE6709F0161
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Genomic Predictors of Outcome in Prostate Cancer.
@en
type
label
Genomic Predictors of Outcome in Prostate Cancer.
@en
prefLabel
Genomic Predictors of Outcome in Prostate Cancer.
@en
P2093
P1433
P1476
Genomic Predictors of Outcome in Prostate Cancer.
@en
P2093
Anders S Bjartell
Hans Lilja
Jack Schalken
Matthew R Cooperberg
Peter J Boström
Scott E Eggener
Thorsten Schlomm
P304
P356
10.1016/J.EURURO.2015.04.008
P407
P577
2015-04-23T00:00:00Z